EUVIMEDEUVIMED entdecken
FallberichtKlinische StudieOpen Access · CC BY-NC 3.0

Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer – A Post Hoc Analysis of METIMMOX Trial Data

Sebastian Meltzer iD, Silje Sjåvik Landmark, Jūratė Šaltytė Benth iD, Anne Negård iD, Hanne Mari Hamre iD, Christian Kersten iD, Eva Hofsli iD, Marianne Grønlie Guren iD, Halfdan Sorbye iD, Kjersti Flatmark iD, Anne Hansen Ree iD

ImmunoTargets and Therapy · 2026-05 · Volume 15 · 1-11

DOI: 10.2147/itt.s594176 ↗

Kurz gefasst

Fallbericht in der Zeitschrift ImmunoTargets and Therapy, 2026-05. Verfasst von Sebastian Meltzer und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oncology, Akershus University Hospital, Lørenskog, Norway. Die Arbeit nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

Stichwörter der Autor:innen

biomarkercarcinoembryonic antigencolorectal cancerimmune checkpoint inhibition

Autor:innen und Institutionen

  • Department of Oncology, Akershus University Hospital, Lørenskog, Norway.
  • Health Services Research Unit, Akershus University Hospital, Lørenskog, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
  • Department of Radiology, Akershus University Hospital, Lørenskog, Norway.
  • Department of Research, Sørlandet Hospital, Kristiansand, Norway.
  • Department of Oncology, St. Olav's Hospital, Trondheim, Norway.

ORCID-Profile: Sebastian Meltzer, Jūratė Šaltytė Benth, Anne Negård, Hanne Mari Hamre, Christian Kersten, Eva Hofsli, Marianne Grønlie Guren, Halfdan Sorbye, Kjersti Flatmark, Anne Hansen Ree

Zitieren

APA

Meltzer, S., Landmark, S. S., Šaltytė Benth, J., Negård, A., Hamre, H. M., Kersten, C., Hofsli, E., Guren, M. G., Sorbye, H., Flatmark, K., & Ree, A. H. (2026). Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer – A Post Hoc Analysis of METIMMOX Trial Data. ImmunoTargets and Therapy, Volume 15, 1-11. https://doi.org/10.2147/itt.s594176

Vancouver

Meltzer S, Landmark SS, Šaltytė Benth J, Negård A, Hamre HM, Kersten C, et al. Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer – A Post Hoc Analysis of METIMMOX Trial Data. ImmunoTargets and Therapy. 2026;Volume 15:1-11. doi:10.2147/itt.s594176

BibTeX
@article{Meltzer2026,
  author = {Meltzer, Sebastian and Landmark, Silje Sjåvik and Šaltytė Benth, Jūratė and Negård, Anne and Hamre, Hanne Mari and Kersten, Christian and Hofsli, Eva and Guren, Marianne Grønlie and Sorbye, Halfdan and Flatmark, Kjersti and Ree, Anne Hansen},
  title = {Carcinoembryonic Antigen Flare Under Oxaliplatin-Based Chemotherapy Predicts Benefit from Nivolumab in Metastatic Microsatellite-Stable Colorectal Cancer – A Post Hoc Analysis of METIMMOX Trial Data},
  journal = {ImmunoTargets and Therapy},
  year = {2026},
  volume = {Volume 15},
  pages = {1--11},
  doi = {10.2147/itt.s594176}
}
Kostenlos starten →